FDA Names New Drugs & Labeling Compliance Division Director
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA New Drugs & Labeling Compliance Division Acting Director Steven Silverman will assume the role on a permanent basis, FDA announced Feb. 5
You may also be interested in...
“Whistleblower” Suits Should Be Encouraged By Rx Manufacturers, Sen. Grassley Says
Schering-Plough’s Claritin settlement prompts letter from Grassley to Schering and 18 other manufacturers. Educating employees about the False Claims Act and their right to file suit is a “step in the right direction” to address fraud, he says.
PBMs Object To Real-Time Prior Authorization As Part Of E-Prescribing
Medco, Express Scripts and Cigna maintain that “automated” prior authorization is not feasible because it requires a discussion with the doctor. The PBMs recommend that HHS should support electronic transmission of prior authorization “where feasible.”
E-Prescriber Access To Non-Preferred Drug Listings Is Industry Concern
Physicians should not have to scroll or click through new windows to see non-preferred and off-formulary drugs, Pfizer, J&J tell the standards subcommittee of the National Committee on Vital & Health Statistics.